Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications

Bibliography

• JUPPNER H, KRONENBERG H: Primer on the metabolic bone diseases and disorders of mineral metabolism. In: Parathyroid Hormone. Favus M (Ed.), American Society for Bone and Mineral Research, Washington DC, USA (2003):117-124.
   Google Scholar
• NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344(19):1434-1441.
   PubMed Web of Science ®Google Scholar
• DEMPSTER DW, COSMAN F, KURLAND ES et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. (2001) 16(10):1846-1853.
   PubMed Web of Science ®Google Scholar
• PIERROZ DD, BOUXSEIN ML, RIZZOLI R, FERRARI SL: Combined treatment with a β-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone (2006) 39(2):260-267.
   PubMed Web of Science ®Google Scholar
• NAKAZAWA T, NAKAJIMA A, SHIOMI K et al.: Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone (2005) 37(5):711-719.
   PubMed Web of Science ®Google Scholar
• KOMATSUBARA S, MORI S, MASHIBA T et al.: Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone (2005) 36(4):678-687.
   PubMed Web of Science ®Google Scholar
• ANDREASSEN TT, WILLICK GE, MORLEY P, WHITFIELD JF: Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif. Tissue Int. (2004) 74(4):351-356.
   PubMed Web of Science ®Google Scholar
• HOLZER G, MAJESKA RJ, LUNDY MW, HARTKE JR, EINHORN TA: Parathyroid hormone enhances fracture healing. A preliminary report. Clin. Orthop. Relat. Res. (1999) 366:258-263.
   Google Scholar
• ANDREASSEN TT, FLEDELIUS C, EJERSTED C, OXLUND H: Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop. Scand. (2001) 72(3):304-307.
   Google Scholar
• ANDREASSEN TT, EJERSTED C, OXLUND H: Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J. Bone Miner. Res. (1999) 14(6):960-968.
   PubMed Web of Science ®Google Scholar
• JAHNG JS, KIM HW: Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Orthopedics (2000) 23(10):1089-1094.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA A, SHIMOJI N, SHIOMI K et al.: Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J. Bone Miner. Res. (2002) 17(11):2038-2047.
   PubMed Web of Science ®Google Scholar
• CHEN H, FRANKENBURG EP, GOLDSTEIN SA, MCCAULEY LK: Combination of local and systemic parathyroid hormone enhances bone regeneration. Clin. Orthop. Relat. Res. (2003) 416:291-302.
   Google Scholar
• SEEBACH C, SKRIPITZ R, ANDREASSEN TT, ASPENBERG P: Intermittent parathyroid hormone (1-34) enhances mechanical strength and density of new bone after distraction osteogenesis in rats. J. Orthop. Res. (2004) 22(3):472-478.
   Google Scholar
• ALKHIARY YM, GERSTENFELD LC, KRALL E et al.: Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J. Bone Joint Surg. (2005) 87(4):731-741.
   PubMed Web of Science ®Google Scholar
• KIM HW, JAHNG JS: Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Iowa Orthop. J. (1999) 19:71-77.
   Google Scholar
• BOSTROM MP, GAMRADT SC, ASNIS P et al.: Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone (2000) 26(5):437-442.
   PubMed Web of Science ®Google Scholar
• SKRIPITZ R, ANDREASSEN TT, ASPENBERG P: Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber. A dose–response study. J. Bone Joint Surg. Br. (2000) 82(1):138-141.
   Google Scholar
• SKRIPITZ R, ASPENBERG P: Implant fixation enhanced by intermittent treatment with parathyroid hormone. J. Bone Joint Surg. Br. (2001) 83(3):437-440.
   Google Scholar
• FANG J, ZHU YY, SMILEY E et al.: Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc. Natl. Acad. Sci. USA (1996) 93(12):5753-5758.
   Google Scholar
• CENTRELLA M, MCCARTHY TL, CANALIS E: Parathyroid hormone modulates transforming growth factor β activity and binding in osteoblast-enriched cell cultures from fetal rat parietal bone. Proc. Natl. Acad. Sci. USA (1988) 85(16):5889-5893.
   Google Scholar
• CANALIS E, CENTRELLA M, BURCH W, MCCARTHY TL: Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest. (1989) 83(1):60-65.
   Google Scholar
• MCCARTHY TL, CENTRELLA M, CANALIS E: Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology (1989) 124(3):1247-1253.
   PubMed Web of Science ®Google Scholar
• DEMPSTER DW, COSMAN F, PARISIEN M, SHEN V, LINDSAY R: Anabolic actions of parathyroid hormone on bone. Endocr. Rev. (1993) 14(6):690-709.
   Google Scholar
• WHITFIELD JF: Parathyroid hormone and leptin – new peptides, expanding clinical prospects. Expert Opin. Investig. Drugs (2005) 14(3):251-264.
   Google Scholar
• WATSON P, LAZOWSKI D, HAN V et al.: Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone (1995) 16(3):357-365.
   PubMed Web of Science ®Google Scholar
• WHITFIELD JF: Osteoporosis-treating parathyroid hormone peptides: what are they? What do they do? How might they do it? Curr. Opin. Investig. Drugs (2006) 7(4):349-359.
   Web of Science ®Google Scholar
• KULKARNI NH, HALLADAY DL, MILES RR et al.: Effects of parathyroid hormone on Wnt signaling pathway in bone. J. Cell. Biochem. (2005) 95(6):1178-1190.
   Google Scholar
• WANG YH, LIU Y, ROWE DW: Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in calvarial osteoblast cultures. Am. J. Physiol. (2007) 292:E594-E603.
   Web of Science ®Google Scholar
• OKAZAKI K, JINGUSHI S, IKENOUE T et al.: Expression of parathyroid hormone-related peptide and insulin-like growth factor I during rat fracture healing. J. Orthop. Res. (2003) 21(3):511-520.
   Google Scholar
• PALMER M, ADAMI HO, KRUSEMO UB, LJUNGHALL S: Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am. J. Epidemiol. (1988) 127(5):1031-1040.
   Web of Science ®Google Scholar
• LANE NE, SANCHEZ S, MODIN GW et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J. Bone Miner. Res. (2000) 15(5):944-951.
   PubMed Web of Science ®Google Scholar
• MILLER PD, BILEZIKIAN JP, DEAL C, HARRIS ST, CI RP: Clinical use of teriparatide in the real world: initial insights. Endocr. Pract. (2004) 10(2):139-148.
   Google Scholar
• CRANNEY A, PAPAIOANNOU A, ZYTARUK N et al.: Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 175(1):52-59.
   PubMed Web of Science ®Google Scholar
• TASHJIAN AH Jr, GAGEL RF: Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J. Bone Miner. Res. (2006) 21(3):354-365.
   PubMed Web of Science ®Google Scholar
• HODSMAN AB, HANLEY DA, ETTINGER MP et al.: Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. (2003) 88(11):5212-5220.
   Google Scholar
• HODSMAN AB, FRAHER LJ, WATSON PH et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. (1997) 82(2):620-628.
   Google Scholar
• BLACK DM, GREENSPAN SL, ENSRUD KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349(13):1207-1215.
   PubMed Web of Science ®Google Scholar
• BODY JJ, GAICH GA, SCHEELE WH et al.: A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. (2002) 87(10):4528-4535.
   Google Scholar
• FINKELSTEIN JS, HAYES A, HUNZELMAN JL et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. (2003) 349(13):1216-1226.
   PubMed Web of Science ®Google Scholar
• KURLAND ES, COSMAN F, MCMAHON DJ et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. (2000) 85(9):3069-3076.
   Google Scholar
• ORWOLL ES, SCHEELE WH, PAUL S et al.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. (2003) 18(1):9-17.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, SAN MARTIN J, MILLER PD et al.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. (2005) 165(15):1762-1768.
   PubMed Web of Science ®Google Scholar
• COSMAN F, NIEVES J, ZION M et al.: Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. (2005) 353(6):566-575.
   PubMed Web of Science ®Google Scholar
• VAHLE JL, SATO M, LONG GG et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. (2002) 30(3):312-321.
   Google Scholar
• VAHLE JL, LONG GG, SANDUSKY G et al.: Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol. (2004) 32(4):426-438.
   Google Scholar
• TASHJIAN AH Jr, CHABNER BA: Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J. Bone Miner. Res. (2002) 17(7):1151-1161.
   PubMed Web of Science ®Google Scholar
• RUBIN MR, BILEZIKIAN JP: Parathyroid hormone as an anabolic skeletal therapy. Drugs (2005) 65(17):2481-2498.
   PubMed Web of Science ®Google Scholar
• SKRIPITZ R, ASPENBERG P: Parathyroid hormone – a drug for orthopedic surgery? Acta Orthop. Scand. (2004) 75(6):654-662.
   Google Scholar
• MORLEY P: Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin. Drug Deliv. (2005) 2(6):993-1002.
   Google Scholar